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Abstract: Epstein-Barr virus related lymphoproliferative  disorders are a rare but potentially 
fatal  complication  of  allogeneic  stem  cell  transplantation  with  an  incidence  of  1
occurring within 6 months after transplantation.  The most relevant risk factors include the 
use of in vivo T-cell depletion with antithymocyte globulin, HLA disparities between donor 
and recipient, donor type,  splenectomy etc. The higher the num
the risk of developing Epstein-
EBV viremia after transplantation is of value and it should be applied to high risk patients 
since  it  allows  pre-emptive  therapy  in
treatment. This strategy might reduce mortality which was >80% prior to the imp
of anti-EBV therapy. Treatment of EBV
therapy (rituximab), adoptive T
considered the first treatment option, preferably guided by intensive monitoring of EBV DNA 
while  reduction of  immunosuppression  should be  carefully  evaluated for  the risk  of graft 
versus host disease.
Introduction: EBV is an ubiquitous lympho
epitheliotropic gamma1-herpesvirus.    Primary 
infection of Epstein-Barr virus (EBV) is transmitted 
by saliva and occurs in childhood in asymptomatic 
manner.  EBV  actively  replicates  in  the  epithelial 
cells  of  the  oropharynx  and  it  can  subsequently 
infects  recirculating  B  lymphocytes.  In    50%  of 
adolescents    primary  EBV  infection  may  lead  to 
acute infectious mononucleosis. This symptomatic 
condition  is  the  consequence  of  the  powerful 
antiviral T cell response to the EBV
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Barr virus related lymphoproliferative  disorders are a rare but potentially 
fatal  complication  of  allogeneic  stem  cell  transplantation  with  an  incidence  of  1
occurring within 6 months after transplantation.  The most relevant risk factors include the 
cell depletion with antithymocyte globulin, HLA disparities between donor 
and recipient, donor type,  splenectomy etc. The higher the numbers of risk factors the higher 
-Barr virus related lymphoproliferative  disorders. Monitoring 
EBV viremia after transplantation is of value and it should be applied to high risk patients 
emptive  therapy  initiation    at  specified  threshold  values      and  early 
treatment. This strategy might reduce mortality which was >80% prior to the imp
. Treatment of EBV-LPD after allogeneic SCT may consist of anti
optive T-cell immunotherapy or both. Rituximab treatment should be 
considered the first treatment option, preferably guided by intensive monitoring of EBV DNA 
while  reduction of  immunosuppression  should be  carefully  evaluated for  the risk  of graft 
EBV is an ubiquitous lympho- and 
herpesvirus.    Primary 
Barr virus (EBV) is transmitted 
by saliva and occurs in childhood in asymptomatic 
manner.  EBV  actively  replicates  in  the  epithelial 
cells  of  the  oropharynx  and  it  can  subsequently 
ymphocytes.  In    50%  of 
adolescents    primary  EBV  infection  may  lead  to 
acute infectious mononucleosis. This symptomatic 
condition  is  the  consequence  of  the  powerful 
antiviral T cell response to the EBV-driven B-cell 
proliferation
1. Immuno-compromised  patien
present  a  lack  of  T-cell  control  that  favours  the 
polyclonal  expansion  of  B
infected  and  immortalized.  These  cells  may  also 
acquire  additional  genetic  lesions  leading  to  
oligoclonality and, eventually, to  monoclonality of 
the B-cell proliferation
2. The immunocompromised 
status  of  patients  after  hemopoietic  stem  cell 
transplantation (SCT) or solid organ transplantation 
(SOT)  may  destroy  the  normal  balance  between 
latently infected B cell proliferation and the EBV
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Barr virus related lymphoproliferative  disorders are a rare but potentially 
fatal  complication  of  allogeneic  stem  cell  transplantation  with  an  incidence  of  1-3%  and  
occurring within 6 months after transplantation.  The most relevant risk factors include the 
cell depletion with antithymocyte globulin, HLA disparities between donor 
bers of risk factors the higher 
Barr virus related lymphoproliferative  disorders. Monitoring 
EBV viremia after transplantation is of value and it should be applied to high risk patients 
itiation    at  specified  threshold  values      and  early 
treatment. This strategy might reduce mortality which was >80% prior to the implementation 
LPD after allogeneic SCT may consist of anti-B-cell 
cell immunotherapy or both. Rituximab treatment should be 
considered the first treatment option, preferably guided by intensive monitoring of EBV DNA 
while  reduction of  immunosuppression  should be  carefully  evaluated for  the risk  of graft 
compromised  patients 
cell  control  that  favours  the 
polyclonal  expansion  of  B-cell  clones  that  are 
infected  and  immortalized.  These  cells  may  also 
acquire  additional  genetic  lesions  leading  to  
oligoclonality and, eventually, to  monoclonality of 
The immunocompromised 
status  of  patients  after  hemopoietic  stem  cell 
transplantation (SCT) or solid organ transplantation 
(SOT)  may  destroy  the  normal  balance  between 
latently infected B cell proliferation and the EBV-Medit J Hemat Infect Dis 2009, 1: Open Journal System
specific  T  cell  response.  Hence,  the  increased 
number  of  latently  infected  B  cells  may  lead  to 
post-transplant  lympho-proliferatives  disorders 
(PTLD)  that  may  have  a  nodal  or  extranodal 
localization into one specific site or may involve the 
allograft after SOT
3.
EBV-related clonal lesions range from policlonal 
plasmacytic hyperplasia to the atypical monoclonal 
polymorphic B-cell hyperplasia until the onset of an 
aggressive non Hodgkin’s lymphoma. The majority 
of PTLD cases are EBV-positive and many show a 
latency  III  pattern  of  gene  expression.  In healthy 
individuals the outgrowth of EBV transformed B-
cells  is  prevented  by  a  cell  mediated  response 
realized  by  cytotoxic  T-lymphocytes  and  MHC-
unrestricted NK cells. The most important control 
against  the  proliferation  of  viral  infected  B  cells 
involves CD8 + specific cytotoxic T cells (CTL), 
which recognize viral epitopes presented by MHC 
Class I molecules on the surface of infected B cell
4.
Definitions: The guidelines on the management of 
EBV  infection  in  patients  with  hematological 
malignancies  and  after  SCT  from  the  Second 
European  Conference  on  Infections  in  Leukemia 
have  been  published  recently
5 and  the  following 
definitions related to diagnosis of EBV infection in 
the  HSCT  setting  have  been    introduced:  EBV-
DNA-emia– detection of EBV-DNA in  the  blood. 
Primary  EBV  infection– EBV  detected  in  a 
previously  EBV-seronegative  patient.  Probable 
EBV  disease– significant  lympho-adenopathy  (or 
other end-organ disease) with high EBV-DNA load 
in  the  blood,  in  the  absence  of  other  etiologic 
factors or established diseases. Proven EBV disease
(PTLD or other end-organ disease) – EBV detected 
from  an  organ  by  biopsy  or  other  invasive 
procedures with a test with appropriate sensitivity 
and specificity together with symptoms and/or signs 
from the affected organ  Pre-emptive therapy in this 
setting  is  defined  as  any  agent  or  specific  cells 
given  to  an  asymptomatic  patient  with  EBV 
detected by a screening assay, while treatment of 
EBV  disease  is  with  agents  or  other  therapeutic 
methods  applied  to  a  patient  with  EBV  disease 
(proven or probable).
PTLD  after  SCT:  origin,  risk  factors  and 
diagnosis: The PTLD is a severe complication of 
prolonged  immunosuppression.  The  first  cases  of 
these disorders  have been described in the contest 
of immunosuppression secondary to SOT. Prior to 
the introduction of cyclosporine A, the occurrence 
of PTLD was extremely rare. The rate of PTLD has 
been significantly increased after the introduction of 
the  triple  therapy  with  cyclosporine,  OKT3 
antibody and antithymocyte globulin (ATG)  but on 
the  other  hand  the  introduction  of  effective 
immunosuppression  has undoubtedly changed the 
rate  of  success  of  SOT  through  a  significant  
prolongation of survival of patients. In this setting  
the incidence has been reported up to 15%.  EBV 
related PTLD following SOT develops, in most of  
the cases, in the first years post transplant
6.  Risk 
factors  for  developing  this  complication  are  the 
degree and duration of immunosuppression and the 
onset  of  the  primary  infection  after  transplant  in 
EBV  naïve  recipients.  A  correlation  between  the 
type  of  transplanted  organ  and  the  occurrence  of 
PTLD  has  been  extensively  reported  in  the 
literature. Thus, the different incidences of PTLD in 
solid organ transplantation are as following:1-3% in 
kidney  and  liver  transplant,  1-6%  in  cardiac 
transplant, 2-6% in combined heart-lung transplant, 
4-10% in lung transplant, and up to 20% in small 
intestine transplant
6.
The majority of cases of PLTD in solid organ 
transplantation  are  of  recipient  origin  although 
recently  the  donor  origin  has  been  consistently 
reported after SOT
7.
The  genetic  origin  of  PTLD  has  been  
determined  by  means  of  different  technique 
including    microsatellite  analysis,  performed  on 
DNA  extracted  from  tumor  cells,  from  donor  
biopsy specimen obtained form transplanted organ 
and from recipient DNA. 
After allogeneic SCT the overall frequencies of 
PLTD  is  about  1%.  In  allogeneic  stem  cell 
transplantation  EBV-PTLD  is  nearly  always    of 
donor  origin. Reddiconto et  al.
8 have described  a 
case of PTLD in a patient with secondary –MDS, 
receiving  double  cord  blood  stem  cell 
transplantation.  The  analysis  of  chimerism  on 
patient biopsy specimens,  documented that 95% of 
malignant cells were of donor origin, in particular, 
of  female  cord  blood  unit  engrafted.  However, 
rarely PTLD may origin from recipient B cells. In a 
case-report of PTLD
2 in a child with acute T cell 
leukemia it was established the recipient origin of 
this  neoplasm.  The  EBV- seropositive  patient 
received graft from an unrelated seropositive donor. 
An  explanation  of  this  peculiar  situation  is  the 
possible  selection  of  clonal  EBV-infected  B 
lymphocytes before  allogeneic transplantation. 
The major risk factors for EBV-PTLD following 
allogeneic  stem  cell  transplantation  are:    T-cell 
depletion of the graft, the use of serotherapy with 
ATG or Campath for prophylaxis and treatment of 
graft versus host disease (GVHD),  transplantation 
from  an  unrelated  or  haploidentical  donor,    cord Medit J Hemat Infect Dis 2009, 1: Open Journal System
blood as source of stem cells in a reduced intensity 
conditioning (RIC) regimen setting,  HLA disparity 
donor-recipient,  duration  of  immunosuppressive 
prophylaxis  and,  finally,  the  type  of  conditioning 
regimen. 
Van Esser et al.
9 showed that the probabilities of
developing EBV reactivation, defined as detection 
of EBV viremia without symptoms,  were high after 
both unmanipulated and TCD-allogeneic SCT and 
were  31%  and  65%,  respectively.    Patients 
receiving a T-cell depleted SCT have a significantly 
higher risk for recurrent EBV reactivations. In this 
study, the main difference between unmanipulated 
and TCD graft was the subsequent development of 
PTLD, this malignancy occurring only after TCD-
SCT.  This  may  be  due  to  an  impaired  ability  of 
these  patients  to  mount  an effective  immune 
response to the reactivating virus. The few number 
of EBV-specific memory T cells in T-cell depleted 
graft  may  play  a  major  role  in  this  condition.  In 
particular, the combination of  T-cell depletion and 
use  of  ATG  mostly  favours  PTLD  development, 
with respect to  only T-cell depletion. 
A  number  of  studies  suggest  that  T  cell 
reconstitution after RIC-regimens may be delayed 
compared  to  conventional  myeloablative 
regimens
10.    In  fact,  RIC  regimens  determine  a 
profound  immunosuppression  rather  than 
myeloablation,  so,  the  subsequent  profound 
immunosuppression  and  prolonged  lymphopenia 
result  in  an  increased  incidence  of  viral 
reactivations and possibly PTLD development. The 
experience  of  Great  Ormond  Street  Hospital
11
reported extensive      monitoring    for  EBV 
reactivation  and  PTLD  development  in  128 
paediatric patients undergoing an allogeneic SCT. 
In  this  cohort,  EBV  viremia  and  PTLD  were 
significantly  more  frequent  after  RIC  than 
conventional  SCT.  In  the  first  group  of  patients 
receiving RIC,  35% of patients (23/65) developed 
EBV  viremia.  Eight  of  these  remained 
asymptomatic, five patients developed symptomatic 
viremia without PTLD and ten patients developed 
PTLD. In contrast, only 8.8% (6/68) of the patients 
receiving  conventional  SCT  developed  EBV 
viremia. All of them  remained asymptomatic and 
none  progressed  to  PTLD
12.    Juvonen  E.  et  al., 
reported  19  cases  of    PTLD  in  a  cohort  of  257 
patients  undergoing  allogeneic  SCT  of  non  T-
depleted  grafts  from  HLA-unrelated    and  sibling 
donors.    Of  the 55  patients  transplanted  from  an 
unrelated donor and treated with ATG as part of the 
conditioning,  15%  (8/55)  developed  PTLD. 
Treatment  of  active  GVHD  was  able  to    favour 
PLTD occurrence. In fact, in the absence of acute 
steroid-resistant  GVHD  requiring  with  ATG,  no 
patients  receiving  a  graft  from  a  sibling  donor 
developed  PTLD.  In  this  study  there  was  also  a 
different  incidence  of  PTLD  with  the  use  of 
different  ATG  commercially  available
13.    In  the 
review reported by Cohen et al.,  almost all reported 
cases of PTLD in RIC transplantation have received 
a  combination of fludarabine and    serotherapy  or 
Campath.  This  combination  is  profoundly 
immunosuppressive and it induce an higher T-cell 
depletion in vivo. This was supported by the lower 
incidence of EBV reactivation observed after RIC 
cord  blood  transplantation  (UCBT),  without ATG 
as part of conditioning regimens
13 although there 
are controversial data in this specific issue. Despite 
some  reports  showing  a  possible  increase  in  the  
risk of EBV-PTLD after UCBT, the rate of PTLD 
appear  to  be  comparable  to  those  reported  after 
HLA-matched  unrelated  myeloablative 
transplantation. Brustein et al. studied 335 UCBT 
after  myeloablative  or  RIC  conditioning  regimen. 
They  observed    an  overall  rate  of  EBV  related 
complication  of  4.5%,  in  particular,  3.3%  for 
myeloablative  transplantations  and  7%  for  non 
myeloablative transplantation. In the setting of non 
ablative transplantation, the use of ATG leads to an 
incidence of EBV related complications up to 20%,  
compared with  2% in the absence of ATG
14.
A feature of PTLD following UCBT is  a longer 
interval for malignancy development compared to  
peripheral  blood  or  bone  marrow  SCT,  in  both 
myeloablative  and  non  myeloablative 
transplantations.  The  absence  of  EBV  specific 
memory T cell in cord blood may account for this 
behaviour.  
In a group of patients receiving Campath in vivo,  
Chakrabarti
10 observed  an  increasing  overall 
incidence of infections and a significantly delayed 
T-cell  recovery.  Nevertheless,  the  incidence  of 
EBV-PTLD was low with alemtuzumab:  1% in a 
cohort of RIC-SCT receiving alemtuzumab in vivo 
and  0%  in  stem  cell  recipients  receiving 
alemtuzumab-treated grafts. This probably reflects 
the ability of this anti-CD52 antibody to decrease 
both  B cells, the EBV reservoir,  and   T cell
15.   
HLA-mismatch may have a role in the pathogenesis 
of PTLD because  immune reconstitution is delayed 
after a mismatched graft and T-lymphocytes remain 
the  most  important  system  in    EBV  infection 
control.
In a  multivariate analysis from Sundin et al.
16
HLA mismatch,    splenectomy,  and    EBV 
seronegativity  of  recipients  were  significant  risk
factors for  PTLD development. The incidence of 
PLTD  was  0.26%  among  patients  without    risk Medit J Hemat Infect Dis 2009, 1: Open Journal System
factors.  Patients  with  one  risk  factor  had  a 
probability of developing PTLD of 8.2% and those 
with  two  risk  factors  a  probability  of  35.7%. 
Interestingly all patients developing PTLD received 
an anti T-cell prophylaxis with ATG.
EBV-DNA  monitoring:  predictivity  of  PTLD 
development  and  role  in  pre-emptive  therapy: 
As PTLD may evolve from a polyclonal disorder to 
a  more  aggressive  monoclonal  variant,  an  early 
diagnosis  is  relevant.  In  the  last  years,    PCR 
monitoring of EBV viral load, a minimally invasive 
technique,  has  been  increasing  for  the  prevention 
and  early  detection  of  post  transplant 
lymphoproliferative disease with the aim of export   
the  successful  paradigm of  CMV  pre-emptive 
strategy  after  SCT.  EBV  viremia  was  initially 
carried out by using qualitative PCR analysis and 
more recently by quantitative PCR technique.
The observed EBV loads in healthy donors are 
very similar in all the studies and are typically very 
low  or  undetectable.  This  depends  on  the  low 
frequency of EBV positive B cells in the circulation 
that are lesser than 10 per 10
6 in healthy carriers. In 
transplant recipients without EBV related diseases, 
the  circulating  viral  load  is  generally  higher  than 
those  reported  in  healthy  donors,  probably  as  a 
consequence of   the  shift  of  the  immune  balance 
towards the virus.
Even  if  the  mean  EBV  load  in  the  peripheral 
blood seems to be higher in  HSCT recipients with 
PTLD,  than  in  recipient  without  PTLD,  patients 
with PTLD may present a broad range of PCR value 
within  1-5  logs.  In  addition,  these  values  often 
overlap with the results of patients not developing 
PTLD. Thus we are not able to detect on the basis 
of  viral  EBV  load    patients  progressing  to  EBV-
PTLD. As a result  pre-emptive treatment is now 
used in patients with increasing viral  load or over 
the threshold of 10
3 copies/ml or 200 copies per 10
5
PBMC, empirically in many transplant centers with 
the aim to reduce the progression rate to PTLD. 
Another obstacle for the interpretation of EBV 
data  after  SCT  is  related  to  different  PCR 
monitoring analysis  in published studies and many 
data  are  based  on retrospective  analysis  of  single 
center  experience.  In addition  there is  no  general 
consensus on which is the best specimen to adopt 
(plasma,  peripheral  blood    mononuclear  cells, 
whole  blood).  In  fact  the  determination  of  cell-
associated EBV DNA loads could be interpreted as 
a  marker  of EBV-induced  cell proliferation while 
plasma levels of EBV DNA could be expression of 
either virus production or the release of episomal 
DNA  from  apoptotic  cells,  or  both
17. A  general 
consensus has been obtained on what should be the 
ideal interval of serial monitoring and this is based 
on the assumption  that  the doubling time of EBV 
viral load can be as short as 46-56 h. Thus, PCR 
monitoring  should  be  performed  once  a  week,  at
least,  in  order  to  optimized  the  detection  of  an 
elevated viral load before the clinical presentation 
of malignancy.  
The sensitivity of  EBV-DNA  for the diagnosis 
of  PTLD  ranges  from  78%  and  100%  in 
symptomatic patients, but is only between 50% and 
80%  when  used  for  preemptive  diagnosis. 
Subclinical reactivation of EBV detectable by PCR 
occurs  from  20%  to  60%  of  HSCT  recipients 
without  any  PTLD  symptoms  and    the  positive 
predictive role of PCR monitoring for EBV remains 
highly variable
18. EBV viremia  by itself  does not 
seems to predict PTLD development . EBV DNA 
levels  are  most  suitable  to  confirm  diagnoses  of 
EBV PTLD, thereby permitting early and effective 
interventions. 
Clinical  symptoms  of  EBV-related  PTLD: 
Manifestations  of  post-transplant  EBV  infection, 
both  primary  and  reactivation,  include  EBV-
associated  enteritis  with  multiple  ulcers,  EBV-
related hepatitis, encephalitis, and fulminant EBV-
associated hemophagocytosis. These complications 
are,  however,  infrequent.  Chronic  active  EBV 
infection  characterized  by  chronic  or  recurrent 
infectious  mononucleosis-like  symptoms  such  as 
fever, hepatosplenomegaly, persistent hepatitis, and 
extensive  lymphadenopathy  has  also  been 
described. The most severe manifestation of EBV 
infections  following  allogeneic  SCT
4. is  EBV-
associated  PTLD.  EBV-associated  tumors 
(reactivation  syndromes)  include  lympho-
proliferative  disease  (LPD),  Burkitt's
lymphoma/non-Hodgkin  lymphoma  (NHL), 
nasopharyngeal carcinoma, natural killer (NK)-cell 
leukemia,  Hodgkin's  disease,  hemophagocytic 
lymphohistiocytosis  and  angioblastic  T-cell 
lymphoma. Histopatological classification has been 
recently updated by the World Health Organization 
(WHO)
19.
Diagnosis of EBV disease:  Diagnosis of LPD or 
PTLD  must  be  based  on  symptoms  and/or  signs 
consistent  with  lymphoproliferative  process 
developing  after  SCT,  together  with  detection  of 
EBV  by  an  appropriate  method  applied  to  a 
specimen  from  the  involved  tissue.  Definitive 
diagnosis  of  EBV-PTLD  requires  biopsy  and 
histological  examination  (including 
immunohistochemistry  or  flow  cytometry  for Medit J Hemat Infect Dis 2009, 1: Open Journal System
CD19+ and CD20+). It is important to remember 
that  CD20  can  be  downregulated  on  lymphoma 
cells  after  therapy.  EBV  detection  in  biopsy 
specimen requires detection of viral antigens or in 
situ hybridization  for  the  EBER  (Epstein–Barr-
encoded RNA) transcripts. 
Definitive diagnosis of LPD or PTLD must be 
based  on  symptoms  and/or  signs  consistent  with 
PTLD  together  with  detection  of  EBV  by  an 
appropriate method applied to a specimen from the 
involved tissue.
Treatment  strategies  for  EBV-related  PTLD: 
The mortality from PTLD after HSCT was >80% 
prior  the  implementation  of    anti-EBV  therapy. 
Treatment strategies for EBV-related PTLD include 
reduction  of  immunosuppression,  anti-B  cell 
monoclonal antibodies, conventional chemotherapy 
and radiation. No effect of antivirals drugs can be 
expected with respect to prevention and treatment 
of EBV-LPD. When PTLD is established, standard 
lymphoma  chemotherapy  is  used  in  combination 
with  rituximab
4 . A  recent  approach  includes  the 
infusions  of  donor-derived  lymphocytes  in  SCT 
patients with PTLD, or infusions of HLA-matched  
EBV-specific  cytotoxic  T  lymphocytes (CTLs)  in 
PTLD  both  after SOT and SCT. 
The reduction of immunosuppression therapy is 
usually  the  first-line  approach  for  PTLD  
transplantation  but  this  may  not  be  feasible  in 
patients with active GVHD.  
The overall success rates of EBV-related PTLD 
were lower than after pre-emptive therapy, reaching 
63% and 88.2% of total EBV-DNA clearance with 
rituximab  and  CTL  therapy,  respectively.  Thus, 
because  of  the  progressive  nature  of  PTLD,    an 
early  or  pre-emptive  treatment  with  either  anti-B 
cell monoclonal antibodies or donor-derived EBV-
specific  cytotoxic-T  lymphocytes  is  appealing
20.
Pre-emptive  strategy  is  now  empirically  used  in 
many  transplant  centers  and  rituximab is  the 
treatment of choice although there are no consistent 
data  on  the  best  dosage,  number  of  doses  and 
interval between doses of rituximab.  
Wagner et al.
21, studied a cohort of 111 patients 
who  underwent  myeloablative  HSCT  from  HLA-
matched  unrelated  donor  or  HLA-mismatched 
sibling donor, all receiving ATG or Campath and  
TCD-graft.  EBV  viral  load  from  of  whole  blood 
was monitored. No patients with consistently low 
EBV  DNA  levels  developed  PTLD.  Sixteen  
patients  presented  EBV-DNA  levels  exceeding 
4000  copies/μg  PBMC  DNA  in  two  or  more 
occasions and nine patients had a single occurrence 
of high EBV load. 
Among  them,  eight  developed  symptoms  of 
PTLD. Hence, the detection of EBV-DNA levels > 
4000 copies /μg PBMC DNA had a sensitivity of 
100%  for  the  prediction  of  early  PTLD  but  a 
specificity  of  only  50%  (8/16).  All    patients 
received treatment: two patients received  CTLs , 
five patients received  rituximab (1-4 dose of 375 
mg/m2/die)  and  another  one  received  CTLs  and 
rituximab.  Clinical  symptoms  associated  with 
PTLD  disappeared  and  EBV  load  decreased  to  a 
normal value in 7 out of 8 patients. 
In another  study,  Van  Esser  et  al.    employed  
PCR  for  an  early  diagnosis  and  pre-emptive 
treatment of the EBV related PTLD. The threshold 
of 1000 copies of viral DNA genome per millilitre 
was set  as the reference level for a high predictive 
value  of  PTLD  development.  They    studied  49 
patients  receiving  a  partial  T-cell  depleted 
transplant  from  HLA-matched  sibling  donor or 
matched unrelated donor. EBV reactivation with a 
viral load above 1000 copies/ml was detected in 17 
out of 49 patients (35%). Among them, 2 patients 
presented  an  active  PTLD  and  received  two 
infusions  of  rituximab,  obtaining    complete  and 
persistent clearance of EBV viral load. The other 15 
patients  presented  a  subclinical  reactivation  and 
were  treated  with  rituximab  pre-emptively. 
Fourteen patients have shown a complete response 
after  a  single  dose  of  rituximab.  The  only  non 
responder  patient  showed  an increased  viral  load 
and a progression to EBV related PTLD and was 
treated with  a second dose of rituximab and DLI 
and achieved a clinical response. Thus, pre-emptive 
rituximab  selectively  administered  to  high-risk 
patients,  abrogates  EBV  reactivation  and reduces 
the incidence of EBV-PTLD
22.
Annels et al.
23,  showed that  EBV specific T cell 
reconstitution may be a second important parameter 
to guide pre-emptive treatment. The authors defined 
the EBV reactivation as an EBV viral load > 1000 
copies  at  2  consecutive  time  points.  This  was 
considered a condition of high risk to develop EBV-
PTLD,  together  with  a  graft  from  an  EBV-
seropositive, unrelated or mismatched family donor 
and ATG administration . Eight out of fifty patients 
presented  these  features  and  were  pre-emptive 
treated with a single standard dose of rituximab. T 
cell reconstitution was studied in  all patients. Six 
out of 8 treated patients  presented a significant T 
cell reconstitution and an EBV specific memory T 
cells  expansion  during  EBV  reactivation,  with  a 
contemporary  decrease  in  EBV  DNA  load. 
Additional  evidence  for  the  antiviral  potential  of 
this  T  cell  reconstitution  was  prospectively 
confirmed by a cohort of 14 HSCT recipients at risk Medit J Hemat Infect Dis 2009, 1: Open Journal System
for EBV-LPD. Three out of 14 patients reactivated 
EBV.  Two  patients  developed  a  significant  and 
rapid T cell expansion during the beginning of viral 
reactivation  and  they  obtained  a  clearing  of  viral 
load  without  rituximab  administration.  T  cell 
recovery was absent only in one patient successfully 
treated with rituximab. 
Table  1. Characteristics  of  patients  receiving  allogeneic 
transplant.
AML:  acute  myeloid  leukemia;  NHL:  non-Hodgkin’s 
lymphoma;  CLL:  chronic  lymphocitic  leukemia;  MF: 
myelofibrosis;  PL:  plasmacell  leukemia;  LL:  lymphoblastic 
lymphoma; HL: Hodgkin’s disease; ALL: acute lymphoblastic 
leukemia;  MM:  multiple  myeloma;  AA:  aplastic  anaemia; 
RAEB:  refractory  anemia  with  excess  blasts    Abl:  ablative; 
RIC: reduced intensity conditioning.; MUD: matched unrelated 
donor;  CB:  cord  blood,  PB:  peripheral  blood;  BM.  bone 
marrow
We  have  prospectively  monitored    EBV 
reactivation  in  a  cohort  of  104  patients  receiving 
HSCT  between  February  2005  and  August  2009. 
Seventy-nine  patients  received  an  allogeneic  SCT 
and  twenty-five  patients  received  an  autologous 
SCT.    EBV  reactivation  rate  was  of  16%  (4/25) 
with a median time to the reactivation of 115 days 
in  the  autologous  SCT  group.  In  allogeneic 
transplant group  EBV reactivation was of 60.76% 
(48/79) with a median time to reactivation of  59 
days  (range  3-840),  and  a  median  value  of  viral 
genome  copies  per  ml  of  1.577.017 (  range  408-
60.000.000) (Table 1). Strikingly the incidence od
EBV reactivation varied across the  different stem 
cell  source  being  more  frequently  after  bone 
marrow  (100%)  or    peripheral  blood  (64.2%) 
transplant  compared  to  CB  graft  (12.5%).  In 
patients receiving  bone marrow transplant  there 
was  an  earlier  viral  reactivation  compared  to 
patients receiving  peripheral or CB  transplant. Due 
to  the  small  number  of  patients  receiving  bone 
marrow  these  data  should  be  interpreted  with 
caution. Type of donor also  affected  the incidence 
and time of reactivation. The  incidence was 86.3% 
using  unrelated  donors  and  57.1%  using  sibling 
transplant (p= 0.016) . In patients  receiving ATG or 
Campath as part of GVHD prophylaxis, the rate of  
reactivation  was  93.3%.  Also  some  patients 
presented  two  or  more  subsequent  viral 
reactivations.  The  major  conditions  affecting 
multiple  reactivations  were  underlying    lympho-
proliferative  diseases  (65.2%),  myeloproliferative 
diseases (36%) at transplant and the occurrence of 
GVHD (64%) (Table 2). 
Table  2. Characteristics    of  patients  with  EBV 
reactivation/PTLD after allogeneic SCT
Patients with EBV 
reactivation 48/79(60.7%) 
Median time of reactivation
(days-range) 55 (3-840)
Median  EBV DNA copies/ml 
(range)
1.577.017,83 
(408-60.000.000)
Number of reactivations
one  24/48 (50%) 
two 17/48 (35.4%)
three 7/48 (14.6%) 
PTLD 5/48 (10.4%)
Patients with peak in 
-region 31/48 (64.6%)  
Patients with Monoclonal 
Gammopathy 22/48 (45.8%)  
Donor (sib/MUD) 28/20
Stem Cell Source PB 43 ,  CB 1 , BM 4  
Conditioning Regimen
(abl/RIC) 21/27
ATG/Campath-1H 11/5
GvHD (acute vs chronic) 18 vs 7
In fourthy-eight patients who reactivated EBV, 
serum protein electrophoresis  was carried out. A -
peak,  indicating  the  presence  of  a  monoclonal 
gammopathy (MG),    was  detected  in  31  patients 
(64.5%).    Twenty-seven    patients  with  MG  were 
further  investigated      with  immunofixation    on 
serum  and  urine.  Monoclonal  gammopathy  was 
present in 22/27 patients  and in 5 patients the Ig 
Total of patients 79
Sex (M/F) 51/28
Median age (range) 44.6 (10-70)
Diagnosis
36 AML, 5 NHL, 1 RAEB-2, 8 CLL, 3 
MF, 1 PL, 4 MM, 1 LL, 1 HD, 18 
ALL,1 AA
Conditioning (Abl/RIC) 37/42
GvHD prophylaxis 22/79 ATG (27.8%)
5/79 (6.3%)Campath-1H
Donor  (sib/MUD) 29/50
Stem cell source
CB 8/79 (10.1%),   
PB 67 /79 (84.8%),
BM 4/79 (5.1%) 
GvHD
(acute vs chronic) 27 vs 24Medit J Hemat Infect Dis 2009, 1: Open Journal System
isotype was not identified (Table 3) .  Subtype was: 
a single IgG monoclonal gammopathy in 11 patients 
(IgGκ in 5 cases, IgGλ in 6 cases), a single IgM 
monoclonal gammopathy in two patients (IgMκ in 
one case and IgMλ in the other one), a single IgAκ 
monoclonal  gammopathy  in  one  patient,  and  a 
double  monoclonal  gammopathy  in  the  others  8 
patients (IgGκ+IgGλ in 3 cases, I IgGκ+IgMλ in 3 
cases, gMλ+IgGλ in one case, and IgMκ+IgGκ in 
the last patient).
Table  3. Monoclonal  Gammopaties  in  EBV  reactivating 
patients 
Six  patients  developed  PTLD  (12.5%  of  the 
patients  with  EBV  reactivation  and  7.6%  of  the 
allo-SCT  recipients).  In  five  of  these,  PTLD 
followed  EBV DNA detection in peripheral blood, 
while in the last patient PTLD was diagnosed by 
biopsy, in the absence of previous EBV detection. 
All  patients with PLTD presented a -peak at the 
serum  protein  electrophoresis.  In  five  patients    a 
monoclonal  gammopathy  was  confirmed  by 
immunofixation:  four  patients  presented  a  single 
monoclonal gammopathy (IgGk in two cases,  IgGλ
in one case and IgAk in one case) and one patient 
presented  a  double  monoclonal  gammopathy 
IgMk+IgGλ (Table 4). 
Treatment with rituximab (375mg/m2/die for 1-4 
doses)  was administered to all  cases of PTLD and 
to others 12 asymptomatic or symptomatic patients 
with  an  high  number  of  EBV  genome  copies  in 
order to avoid the progression to PTLD. The vast 
majority of patients (88.9%) treated with rituximab  
showed a sharp viral load clearance. In  11 out of 18 
patients treated with rituximab (61%) abnormalities 
of  serum  protein  electrophoresis  normalized  after 
treatment.  After  rituximab,  immunofixation  was  
evaluated only in 10 out 18 treated patients. Five of 
the these patients showed the complete resolution of 
the MG after treatment. Two patients with PTLD 
died early after treatment:  one patient from multi-
organ failure and  the other because of progressive 
disease.  The  remaining  four  patients  presented 
resolution of symptoms and a drop in  EBV viremia 
in peripheral blood until its disappearance. They are 
alive at follow-up with an overall survival of 6,12, 
13 and 45 months, respectively.
Table 4. Characteristics of patients with PTLD
Patients with PTLD 6
Patients with EBV + PCR 5/6 (83.3%)
     Patients with histological 
diagnosis of PTLD 2/6 (33.3%)  
Donor 6 MUD
Stem Cell Source 5/6 (83.3%) PB
1/6 (16.6%) CB
Conditioning Regimen
(abl/RIC) 4/2 
GVHD prophylaxis 5/6 (83.3%) ATG
1/6 (16.6%) Campath-1H
Presence of -peak 6/6
Presence of Monoclonal 
Gammopathy
IgGk
IgGλ
IgAk
IgMk+IgGλ
5/6 (83.3%)  
2/5 (40%)  
1/5 (20%)  
1/5 (20%)  
1/5 (20%)  
GvHD (acute vs chronic) 2 vs 1
Hence, the risk factors reported in the literature 
are  substantially  confirmed  in  this  prospective 
study.  Rituximab was  effective  for  a  prompt 
treatment  of  PTLD  and  useful  as  pre-emptive 
treatment    limiting  the  progression  of  EBV 
reactivation  to  PTLD.  Monoclonal  gammopathy 
may help to define  patients with EBV viremia at 
high  risk  of  PTLD  after  SCT
24. After  SOT  the 
presence  of  monoclonal  gammopathy  (MG)  after 
organ transplantation has already been considered a 
risk factor for the development of PTLD
25,26,27.
EBV reactivation 48 pts
Presence of -peak 31 pts
Presence of monoclonal 
gammopathy 22
IgG
11 
5  IgGk
6 IgGλ
IgM
2 
1  IgMk
1 IgMλ
IgAk 1 
IgGk+IgGλ 3 
IgMλ+IgGλ 1 
IgGK+IgMλ 3 
IgMk+IgGk 1 Medit J Hemat Infect Dis 2009, 1: Open Journal System
Table 5. Cumulative results of various therapeutic approaches in preemptive therapy and therapy of PTLD adapted from  Styczynski 
et al
20
Conclusions:  In  summary,  treatment  options 
include  manipulation  of  the  balance  between 
outgrowing  EBV-infected  B  cells  and  the  EBV 
CTLs  response  targeting  the  B  cells  with 
monoclonal  antibody  rituximab  and  conventional 
chemotherapy.  The  efficacy  of  this  strategy  is 
greater in early PTLD than in later disease. In the 
case of EBV-specific CTL it should be noted that 
this approach is not widely available. Rituximab is 
useful as a pre-emptive treatment  in patients with 
high EBV viral load and with risk factors for PTLD 
(Table 5). Over-treatment is the rule and it has been 
calculated that at least 5.6 patients will be treated 
unnecessary  in order to prevent 1 single case of 
EBV-PTLD
18.
With  current  approaches  the  mortality  from 
EBV-PTLD can  be  significantly  reduced  but  pre-
emptive treatment based on EBV viremia should be 
validate and diagnostic tests should be standardized 
in  prospective trials. The search for unrecognized 
risk  factors  for  EBV-related  LPD  after  SCT  is 
ongoing  and  includes  biomarkers,  immune-
phenotype  and  genetic  polymorphisms  of  both 
recipient and donor.
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